Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20815516 | 1.00 | CASP3 (0.47) | CASP3SENP8SENP7SENP6TRPA1 | |
| SCHEMBL28798157 | 0.84 | MEN1 (0.54) | CASP3SENP8SENP7SENP6PDE5A | |
| SCHEMBL21008132 | 0.82 | MEN1 (0.45) | CASP3SENP8SENP7SENP6TRPA1 | |
| SCHEMBL10123058 | 0.81 | TTR (0.47) | CASP3SENP8SENP7SENP6TRPA1 | |
| SCHEMBL10447650 | 0.79 | RELA (0.49) | CASP3SENP7KMT2AMEN1ADORA3 | |
| (Z)-1,2-Diphenylethene SCHEMBL29134000 | 0.75 | MAOB (0.69) | TRPA1KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL20815523 | 0.74 | PDE5A (0.46) | CASP3SENP8SENP7SENP6PDE5A | |
| SCHEMBL28773675 | 0.74 | HRH4 (0.58) | KMT2AMEN1ALDH1A1HPGDLMNA | |
| SCHEMBL19084458 | 0.74 | ALDH1A1 (0.62) | CASP3SENP8SENP7SENP6PDE5A | |
| SCHEMBL31484371 | 0.74 | HRH4 (0.58) | KMT2AMEN1ALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3456712-B1 | NOVEL 2,4,6-TRISUBSTITUTED S-TRIAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | NANJING SHIQI PHARMACEUTICAL CO LTD (CN) | 2022-04-20 | — | — | EP | disclosed |
| US-20200190042-A1 | NOVEL 2,4,6-TRISUBSTITUTED S-TRIAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | ALUDA PHARMACEUTICALS, INC. | 2020-06-18 | — | — | US | disclosed |
| WO-2017193954-A1 | NOVEL 2,4,6-TRISUBSTITUTED S-TRIAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 南京世其医药科技有限公司 | 2017-11-16 | — | — | WO | disclosed |
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | STK25, STK35, SGK2 | CASP3 1754/4885SENP8 2867/4885SENP7 2476/4885 |
| US-20200190042-A1 | NOVEL 2,4,6-TRISUBSTITUTED S-TRIAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | VIM, HASPIN, WASF2 | CASP3 952/4885SENP8 88/4885SENP7 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.